期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 40, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13046-021-01952-4
关键词
N6-methyladenosine; Signal transduction pathway; Cancer progression; Therapy; RNA fate
类别
资金
- National Natural Science Foundation of China [81772928, 81772901, 81803025, 81872278, 81972776, 82072374, 82073135, 82003243, U20A20367]
- Overseas Expertise Introduction Project for Discipline Innovation (111 Project) [111-2-12]
- Natural Science Foundation of Hunan Province [2019JJ50354, 2019JJ50872, 2020JJ4766, 2020JJ4125]
N6-methyladenosine (m6A) modification is a reversible epigenetic modification that regulates the expression levels of mRNA and noncoding RNA by modulating the fate of RNA molecules. Dysregulation of m6A modification, especially in human tumors, affects different signal transduction pathways and is involved in biological processes of tumor cell proliferation, apoptosis, invasion, migration, and metabolic reprogramming.
The N6-methyladenosine (m6A) modification is a dynamic and reversible epigenetic modification, which is co-transcriptionally deposited by a methyltransferase complex, removed by a demethylase, and recognized by reader proteins. Mechanistically, m6A modification regulates the expression levels of mRNA and nocoding RNA by modulating the fate of modified RNA molecules, such as RNA splicing, nuclear transport, translation, and stability. Several studies have shown that m6A modification is dysregulated in the progression of multiple diseases, especially human tumors. We emphasized that the dysregulation of m6A modification affects different signal transduction pathways and involves in the biological processes underlying tumor cell proliferation, apoptosis, invasion and migration, and metabolic reprogramming, and discuss the effects on different cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据